Elliot B Tapper, MD, FAASLD
Manage Your Profile
About
Elliot B. Tapper MD is a Professor in the Division of Gastroenterology and Hepatology. He is Academic Chief of Hepatology. His primary goal is to empower patients to enjoy a high quality of life. He is an expert in the management of chronic liver disease, performance of clinical trials, and big data for the study of liver disease. He has developed strategies that reduce symptoms and improve quality of life and invented tools that have helped keep patients with cirrhosis at home and away from the hospital. He is the Editor-in-Chief of Hepatology Communications.
Center Memberships
-
Center MemberInstitute for Healthcare Policy and Innovation
-
Center MemberAI and Digital Health Innovation
-
Center MemberEisenberg Family Depression Center
Research Overview
1. Patient reported outcomes (PROs) and symptoms of cirrhosis: We seek to characterize the burden, determinants, and impact of poor health related quality of life and symptoms in cirrhosis. We conduct clinical trials that aim to alleviate these symptoms.
2. Frailty and sarcopenia: Prior work has focused on defining the burden and impact of frailty and sarcopenia, the relationship between hepatic encephalopathy and frailty, and the development of risk-assessment tools. Current research is focused on nutritional, behavioral, and pharmacological interventions to improve and prevent frailty.
3. Hepatic encephalopathy (HE): We aim to optimize risk stratification for overt HE and its complications with a focus on hospitalization and falls and to develop interventions to prevent HE.
4. Quality improvement: We utilize electronic interventions to standardize care, improve quality indicators, integrate patient reported outcomes in care delivery, and reduce patient harms.
Recent Publications
-
Tranah TH, Kronsten VT, Frolkis A, Seager M, Mangini C, Ntuli Y, Montagnese S, Shawcross DL, Tapper EB. Frontline Gastroenterology, 2026 Jul 1; 17 (4): 357 - 369.Journal ArticleHepatic encephalopathy: Part 3, outpatient management
DOI:10.1136/flgastro-2026-103734 -
Yoder L, Tapper EB, Kalman R, Rinella M, Bendin N, Verma M, Pike F, Chalasani N, Nalumasu N, Orman ES. Hepatol Commun, 2026 Jul 1; 10 (7):Journal ArticleThe Transitional Liver Clinic: Study protocol for a stepped-wedge cluster randomized trial.
DOI:10.1097/HC9.0000000000000990 PMID: PMC13286549 -
Tapper E. 2026 Jun 12;PresentationDigital therapeutics for alcohol-related liver disease
-
Tapper E. 2026 Jun 12;PresentationManagement of Mental Health Disorders in Chronic Liver Disease
-
Khalili M, Gurra M, Simonetto D, Terrault N, Bonner L, Goldberg D, Bajaj J, Sanyal AJ, Welch N, Hameed B, Parikh ND, Tapper E, Loomba R, Tincopa M, Jones P, Verna E, Brown RS, Moylan C, Kamath PS, Kappus MR, Dasarathy S. Journal of Hepatology, 2026 May 28; 84: s116 - s117.Journal ArticleFRI-061 Hazardous alcohol use amongst persons with compensated cirrhosis from different etiologies: a liver cirrhosis network study
DOI:10.1016/s0168-8278(26)00533-7 -
Buckholz A, Kardashian A, Goldberg D, Parikh ND, Khalili M, Abdelmalek MF, Hameed B, Kappus MR, Tincopa M, Welch N, Sanyal AJ, Jones P, Shah V, Rosenblatt R, Loomba R, Dinani A, Dasarathy S, Terrault N, Kan A, Smith A, Tapper E, Bajaj J. Journal of Hepatology, 2026 May 28; 84: s190Journal ArticleWED-421 Food insecurity, frailty, and oral health are key drivers of impaired quality of life in a large US multicenter cohort of adults with compensated cirrhosis
DOI:10.1016/s0168-8278(26)00710-5 -
Wegermann K, Smith A, Dasarathy S, Welch N, Verna E, Brown RS, Moylan C, Kamath PS, Shah V, Jones P, Tapper E, Loomba R, Sirlin C, Hameed B, Stolz A, Sanyal AJ, Bajaj J, Ladner D, Khalili M, Terrault N, Parikh ND, Goldberg D. Journal of Hepatology, 2026 May 28; 84: s197 - s198.Journal ArticleWED-447 Baseline characteristics of a prospective, multi-center study on the natural history of compensated cirrhosis: the liver cirrhosis network
DOI:10.1016/s0168-8278(26)00728-2 -
Girard J, Tapper EB, Chen VL. Clin Mol Hepatol, 2026 Apr 24;Journal ArticlePredictive modeling and clinical decision tools for risk stratification in steatotic liver disease.
DOI:10.3350/cmh.2026.0204 PMID: 42044878
Featured News & Stories
Drug candidate treats severe fatty liver disease by protecting the gut in animal models
Managing cirrhosis pain without drugs
Lactulose and tai chi show promise preventing falls for cirrhosis patients
CME Event - 28th Annual Liver Disease Wrap-Up
Internal Medicine Faculty Spotlight − Dr. Elliot Tapper